Advertisement
Organisation › Details
I-Mab Biopharma Co., Ltd. (Shanghai: IMAB)
I-Mab is a dynamic and fast-growing global player committed to developing innovative biologics in the areas of immuno-oncology and immuno-inflammation through internal R&D capabilities and global partnerships. I-Mab's pipeline is driven by the company's development strategy to address unmet needs in China and to bring innovative assets to the world. Following the recent Series B financing of $150 million and rapid growth in internal R&D capabilities, I-Mab is now well positioned to advance its China portfolio of multiple Phase 2 and Phase 3 innovative clinical assets and its global portfolio of first-in-class and best-in-class assets in China and/or US in 2018. I-Mab's long-term commitment is to deliver transformational medicines to patients globally with a focus on unmet needs in China. *
Start | 2017-11-30 existent | |
Group | I-Mab (Group) | |
Industry | biopharmaceutical | |
Industry 2 | drug development | |
Person | Zang, Jingwu (I-Mab 201711 CEO + Founder of I-Mab Biopharma before GSK RnD China 200705 Head) | |
Person 2 | Lin, Raven (I-Mab 201711 Head of Business Development at I-Mab Biopharma) | |
Region | Shanghai | |
Country | China | |
City | n. a. | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: MorphoSys AG. (11/30/17). "Press Release: MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-Mab". Planegg. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for I-Mab (Group)
- [1] MorphoSys AG. (10/14/19). "Press Release: MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China". Planegg & Shanghai....
- [2] MorphoSys AG. (5/7/19). "Press Release: MorphoSys AG Reports First Quarter 2019 Results". Planegg....
- [3] MorphoSys AG. (11/15/18). "Press Release: MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210". Planegg....
- [4] MorphoSys AG. (11/5/18). "Press Release: MorphoSys AG Announces Third Quarter 2018 Results". Planegg....
- [5] MorphoSys AG. (8/8/18). "Press Release: MorphoSys and I-Mab Biopharma Announce China IND Submission of TJ202/MOR202"....
- [6] MorphoSys AG. (11/30/17). "Press Release: MorphoSys Signs Regional License Agreement for Antibody MOR202 with I-Mab". Planegg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top